FDA Compliance: Human Cell & Tissue Products in Office

To satisfy FDA compliance requirements for human cell tissue products medical office environments, clinical practices must adhere to 21 CFR Part 1271 regulations governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Medical practices must ensure products meet Section 361 criteria—requiring minimal manipulation and homologous use—while maintaining strict chain-of-custody logging, temperature monitoring, donor eligibility documentation, and vendor qualification protocols. Practices using non-compliant or Section 351-regulated biologics without an approved Biologics License Application (BLA) risk severe regulatory enforcement and operational liability.

Understanding 21 CFR Part 1271: Section 361 vs. Section 351

The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products under Title 21 of the Code of Federal Regulations, Part 1271. For practice managers and clinical directors integrating biologics into their practice, understanding the distinction between Section 361 and Section 351 products is the foundation of regulatory risk management.

Section 361 HCT/Ps (Human Cells and Tissues)

Section 361 products are regulated solely to prevent the introduction, transmission, and spread of communicable diseases. To qualify as a 361 HCT/P, a tissue product must meet four distinct criteria:

1. Minimal Manipulation: Processing must not alter the relevant biological characteristics of the tissue.
2. Homologous Use: The tissue must perform the same basic function in the recipient as in the donor.
3. No Combination: The product cannot be combined with another article (such as drugs or synthetic matrices), except for water, crystalloids, or approved sterilizing/preserving agents.
4. Systemic Effect: The tissue must not rely on the metabolic activity of living cells for its primary function (unless intended for autologous use or allogeneic use in first- or second-degree blood relatives).

If a product satisfies all four conditions, it does not require pre-market approval or a Biologics License Application (BLA).

Section 351 Biologics

If an HCT/P fails to meet any one of the Section 361 criteria—for example, if an umbilical cord or amniotic product is marketed for systemic disease treatment, heavily processed, or altered to act as a drug—it is classified as a Section 351 biologic or drug. Section 351 products require an approved Investigational New Drug (IND) application or an active BLA before commercial distribution and clinical use.

Core FDA Compliance Requirements for Medical Office Workflows

Integrating tissue products into clinical protocols requires institutional controls that extend far beyond clinical documentation. Practice administrators must establish verifiable chain-of-custody policies from receiving to administration.

Vendor Qualification and Registration Verification

Practices must confirm that any tissue bank or supplier providing allografts is registered with the FDA Center for Biologics Evaluation and Research (CBER) via the FDA Establishment Registration system. Suppliers must maintain compliant Current Good Tissue Practice (cGTP) facilities.

Storage, Handling, and Environmental Monitoring

Allografts, amniotic membranes, and cellular products require strict temperature controls. Medical offices must utilize validated medical-grade cold storage units equipped with automated temperature logging and threshold alarm systems. Ambient, refrigerated, and ultra-low freezer storage logs should be audited weekly.

Donor Eligibility Documentation

Every tissue unit received must be accompanied by a Summary of Records (SOR) certifying donor screening and infectious disease testing performed in CLIA-certified laboratories.

Complete Traceability and Patient Record Linking

FDA regulations mandate end-to-end tissue tracking. Medical records must explicitly capture:

• Tissue manufacturer and supplier details
• Lot number, serial number, and expiration date
• Specific anatomical site of administration
• Date and time of thawing, preparation, and administration
• Clinician responsible for administration

Mandatory Adverse Event Protocols

Practices must establish clear procedures for identifying, documenting, and reporting adverse events or suspected communicable disease transmission to both the tissue supplier and relevant regulatory authorities.

Operational vs. Clinical Responsibilities in HCT/P Administration

Achieving full compliance requires clear segregation and alignment of operational management and clinical leadership duties.

The Practice Manager's Operational Compliance Checklist

Practice managers overseeing procurement and risk management should audit the following items quarterly:

• FDA Registration Audit: Verify that all tissue vendors maintain active FDA Establishment Registrations.
• Cold Chain Verification: Inspect temperature logs for all storage freezers and refrigerators to ensure no unauthorized excursions occurred.
• Lot Number Reconciliation: Cross-reference incoming packing slips against patient charts to verify 100% tissue lot tracking accuracy.
• SOP Maintenance: Ensure Standard Operating Procedures for handling, receiving, and disposing of tissue products are updated and signed by current staff.
• Supplier Quality Agreements: Maintain documented quality agreements with suppliers outlining tissue handling and notification protocols for product recalls.

The Clinician's Role: Homologous Use and On-Label Application

While practice managers oversee administrative tracking, clinicians bear direct responsibility for intent and application. For pain management doctors and regenerative medicine doctors, maintaining compliance requires that all clinical documentation reflects true homologous use.

Clinicians must accurately document the anatomical purpose of the structural tissue allograft (e.g., providing a protective barrier or structural covering over damaged connective tissue). Documenting non-homologous indications—such as claims of systemic disease cure or organ regeneration—can inadvertently reclassify an otherwise compliant Section 361 tissue into an unapproved Section 351 drug, creating legal and regulatory vulnerability for the medical practice.

Risk Management and Vendor Vetting Standard Operating Procedures

Distributing and acquiring biological tissue products requires rigorous vendor vetting. Practice procurement managers should avoid suppliers who utilize aggressive direct-to-consumer marketing, make unsubstantiated curative claims, or fail to provide transparent donor eligibility documentation.

When evaluating a supply partner, request:

1. FDA Form 2831 Establishment Registration copy
2. Tissue bank accreditation certificates (e.g., AATB)
3. Sample Certificates of Analysis (CoA) and Summaries of Records
4. Written procedures for lot tracking and recall notifications

Establishing transparent supplier relationships protects practice operations and ensures patient safety standards are consistently met.

What This Means for Your Practice: Concrete Next Actions

To ensure your facility meets current FDA compliance requirements for human cell tissue products medical office operations, execute these immediate practical steps:

1. Conduct an Internal Audit: Pull ten recent patient charts involving tissue products and verify that lot numbers, donor summaries, and anatomical sites are fully documented.
2. Inspect Storage Systems: Verify that cold storage units use continuous digital logging rather than manual once-daily checks.
3. Review Marketing and Clinical Statements: Audit your practice website, patient intake forms, and clinical notes to remove any non-homologous claims regarding cellular tissue treatments.
4. Standardize Procurement: Establish a formalized vendor intake checklist before onboarding new biological product lines.

Navigating regulatory frameworks requires ongoing vigilance and reliable supply partners. Learn more about administrative standards by reviewing our FAQ section or reviewing operational best practices for clinical groups.

For custom guidance on setting up compliant procurement protocols or evaluating regenerative medical supplies and devices, contact our clinical operations team today.